Stockreport

Inventiva Phase 2 study for MASH drug meets primary endpoint [Seeking Alpha]

Inventiva S.A. - American Depository Shares  (IVA) 
PDF Lanifibranor was tested in combination with empagliflozin in patients with metabolic dysfunction-associated steatohepatitis, or MASH, also known as non-alcoholic steato [Read more]